UK markets closed
NIKKEI 225
38,179.46 -49.65 (-0.13%) HANG SENG
19,115.06 +151.38 (+0.80%) CRUDE OIL
79.21 +0.95 (+1.21%) GOLD FUTURES
2,343.90 -31.10 (-1.31%) DOW
39,431.51 -81.33 (-0.21%) Bitcoin GBP
50,261.18 +1,403.67 (+2.87%)
BioMarin Pharmaceutical Inc. (BM8.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 08:12AM CEST
| Previous close | 75.66 |
| Open | 75.14 |
| Bid | 74.66 x 2300 |
| Ask | 74.70 x 2200 |
| Day's range | 75.14 - 75.14 |
| 52-week range | 70.78 - 90.52 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 14.268B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 76.67 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
- GuruFocus.com
Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
On May 2, 2024, Jeffrey Ajer, the Executive Vice President and Chief Commercial Officer of Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 5,000 shares of the company.
- Zacks
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
© 2024 Yahoo. All rights reserved.